Ventyx Biosciences, a San Diego-based clinical-stage biopharmaceutical company, develops small molecule therapeutics for autoimmune diseases with a pipeline including VTX002, VTX958, VTX2735, and VTX3232. The company went public on October 21, 2021, and employs 74 people.
Ventyx Biosciences (VTYX) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Ventyx Biosciences's actual EPS was -$0.41, beating the estimate of -$0.55 per share, resulting in a 25.74% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
